A review of clinical trials of human papillomavirus prophylactic vaccines
JT Schiller, X Castellsagué, SM Garland - Vaccine, 2012 - Elsevier
End of study analyses of the phase III trials of prophylactic human papillomavirus (HPV)
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …
virus-like particle (VLP) vaccines in young women are now largely completed. Two distinct …
[HTML][HTML] European guidelines for quality assurance in cervical cancer screening. —summary document
Abstract European Guidelines for Quality Assurance in Cervical Cancer Screening have
been initiated in the Europe Against Cancer Programme. The first edition established the …
been initiated in the Europe Against Cancer Programme. The first edition established the …
Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial
Background Vaccination against the most common oncogenic human papillomavirus (HPV)
types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers …
types, HPV-16 and HPV-18, could prevent development of up to 70% of cervical cancers …
[HTML][HTML] Papillomavirus genome structure, expression, and post-transcriptional regulation
ZM Zheng, CC Baker - Frontiers in bioscience: a journal and virtual …, 2006 - ncbi.nlm.nih.gov
Papillomaviruses are a group of small non-enveloped DNA tumor viruses whose infection
usually causes benign epithelial lesions (warts). Certain types of HPVs, such as HPV-16 …
usually causes benign epithelial lesions (warts). Certain types of HPVs, such as HPV-16 …
[HTML][HTML] The carcinogenicity of human papillomavirus types reflects viral evolution
Persistent infections with carcinogenic human papillomaviruses (HPV) cause virtually all
cervical cancers. Cervical HPV types (n> 40) also represent the most common sexually …
cervical cancers. Cervical HPV types (n> 40) also represent the most common sexually …
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine
Background: Human papillomavirus (HPV) vaccine may be commercially available in a few
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …
years. We explored the clinical benefits and cost-effectiveness of introducing an HPV16/18 …
Vaccines against human papillomavirus and cervical cancer: promises and challenges
Abstract Learning Objectives After completing this course, the reader will be able to: Discuss
the epidemiology and pathogenesis of HPV and HPV-associated diseases. Explain the …
the epidemiology and pathogenesis of HPV and HPV-associated diseases. Explain the …
Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening
M Arbyn, J Dillner - Journal of Clinical Virology, 2007 - Elsevier
The recognition of a strong etiological relationship between infection with high-risk human
papillomavirusses and cervical cancer has prompted research to develop and evaluate …
papillomavirusses and cervical cancer has prompted research to develop and evaluate …
Vaccination against multiple HPV types
EH Elbasha, AP Galvani - Mathematical biosciences, 2005 - Elsevier
Vaccines against the most common human papillomavirus (HPV) types are currently under
development. Epidemiologic data suggest that the transmission dynamics of different HPV …
development. Epidemiologic data suggest that the transmission dynamics of different HPV …
Vaccination to prevent and treat cervical cancer
Human papillomaviruses (HPVs) are the primary etiologic agents of cervical cancer. Thus,
cervical cancer and other HPV-associated malignancies might be prevented or treated by …
cervical cancer and other HPV-associated malignancies might be prevented or treated by …